On Monday, the domestic benchmark indices witnessed a sharp decline as Sensex fell by 540 points or 1.33 per cent to close at 40,145.50 levels while Nifty ended at 11,767.75 levels, down by 162.60 points or 1.36 per cent.

Alembic Pharmaceuticals Limited announced that it has received the final approval from US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Timolol Maleate ophthalmic gel-forming solution, 0.25 per cent and 0.5 per cent.

As per the press release on the stock exchanges, the bid for the project stands at the cost of Rs 1,905 crore. The stated project will have a completion period target of 24 months and its operational period will be 15 years from the date of completion.

The last three years have been quite difficult for mutual fund investors. However, there are some categories that have outshined during the same period.

The company is evaluating and concluding strategic options towards focussed portfolio enhancement with the ultimate objective of enhancing stakeholder values.

In the past few weeks, the domestic markets witnessed strong bullish sentiments. On Monday, bears charged ahead as Sensex declined by more than 500 points while Nifty fell by around 140 points.

On Monday, Tata Communications jumped 4.92 per cent and was trading at Rs 965.70, gaining by Rs 45.30 per share from its previous close.

The market opened in red on October 26, 2020.

The market opened in red on October 26, 2020, overall volumes in futures & options currently stand at 1,58,48,172 contracts with a turnover of Rs. 11,64,474.69 crore.

The market opened in red on October 26, 2020, overall volumes in futures & options currently stand at 1,58,48,172 contracts with a turnover of Rs. 11,64,474.69 crore.